Lantern Pharma (LTRN) Competitors $4.13 -0.03 (-0.72%) As of 09:55 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LTRN vs. VTYX, TIL, CLLS, CGTX, ACOG, NVCT, GLSI, CLYM, PLX, and THTXShould you be buying Lantern Pharma stock or one of its competitors? The main competitors of Lantern Pharma include Ventyx Biosciences (VTYX), Instil Bio (TIL), Cellectis (CLLS), Cognition Therapeutics (CGTX), Alpha Cognition (ACOG), Nuvectis Pharma (NVCT), Greenwich LifeSciences (GLSI), Climb Bio (CLYM), Protalix BioTherapeutics (PLX), and Theratechnologies (THTX). These companies are all part of the "pharmaceutical products" industry. Lantern Pharma vs. Its Competitors Ventyx Biosciences Instil Bio Cellectis Cognition Therapeutics Alpha Cognition Nuvectis Pharma Greenwich LifeSciences Climb Bio Protalix BioTherapeutics Theratechnologies Lantern Pharma (NASDAQ:LTRN) and Ventyx Biosciences (NASDAQ:VTYX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment. Does the media favor LTRN or VTYX? In the previous week, Lantern Pharma had 3 more articles in the media than Ventyx Biosciences. MarketBeat recorded 4 mentions for Lantern Pharma and 1 mentions for Ventyx Biosciences. Ventyx Biosciences' average media sentiment score of 0.00 beat Lantern Pharma's score of -0.46 indicating that Ventyx Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantern Pharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Ventyx Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is LTRN or VTYX more profitable? Ventyx Biosciences' return on equity of -48.89% beat Lantern Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Lantern PharmaN/A -99.89% -81.58% Ventyx Biosciences N/A -48.89%-44.87% Do analysts prefer LTRN or VTYX? Lantern Pharma presently has a consensus target price of $25.00, indicating a potential upside of 505.33%. Ventyx Biosciences has a consensus target price of $7.50, indicating a potential upside of 167.95%. Given Lantern Pharma's stronger consensus rating and higher possible upside, research analysts clearly believe Lantern Pharma is more favorable than Ventyx Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantern Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Ventyx Biosciences 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has higher earnings and valuation, LTRN or VTYX? Lantern Pharma is trading at a lower price-to-earnings ratio than Ventyx Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLantern PharmaN/AN/A-$20.78M-$1.78-2.32Ventyx BiosciencesN/AN/A-$135.12M-$1.68-1.67 Do institutionals & insiders have more ownership in LTRN or VTYX? 28.6% of Lantern Pharma shares are owned by institutional investors. Comparatively, 97.9% of Ventyx Biosciences shares are owned by institutional investors. 8.5% of Lantern Pharma shares are owned by insiders. Comparatively, 18.2% of Ventyx Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more volatility and risk, LTRN or VTYX? Lantern Pharma has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500. Comparatively, Ventyx Biosciences has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. SummaryVentyx Biosciences beats Lantern Pharma on 7 of the 12 factors compared between the two stocks. Get Lantern Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LTRN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LTRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LTRN vs. The Competition Export to ExcelMetricLantern PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.25M$3.16B$5.79B$10.46BDividend YieldN/A2.36%5.61%4.57%P/E Ratio-2.3521.03348.7126.86Price / SalesN/A447.99554.60125.65Price / CashN/A44.8326.0131.15Price / Book2.119.8315.876.50Net Income-$20.78M-$52.82M$3.29B$271.25M7 Day Performance0.73%3.07%200.39%3.27%1 Month Performance-8.43%5.37%184.31%8.15%1 Year Performance4.56%16.89%330.08%26.52% Lantern Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LTRNLantern Pharma1.9869 of 5 stars$4.13-0.7%$25.00+505.3%+4.3%$45.25MN/A-2.3520VTYXVentyx Biosciences1.8132 of 5 stars$2.30flat$7.50+226.1%+23.0%$164.01MN/A-1.3730News CoverageTILInstil Bio2.6204 of 5 stars$25.78+7.0%$88.50+243.3%-70.8%$162.69MN/A-2.00410CLLSCellectis2.0437 of 5 stars$2.99+3.5%$4.00+33.8%+62.6%$160.64M$49.22M-3.65290Analyst UpgradeGap UpCGTXCognition Therapeutics3.044 of 5 stars$1.54-29.0%$2.83+84.0%+146.7%$159.55MN/A-2.3020Positive NewsACOGAlpha Cognition1.9582 of 5 stars$9.45-3.6%$20.00+111.6%N/A$158.38MN/A-5.91N/APositive NewsGap UpNVCTNuvectis Pharma2.3093 of 5 stars$6.19+0.5%$15.33+147.7%-1.1%$156.81MN/A-5.298GLSIGreenwich LifeSciences1.4324 of 5 stars$11.68+4.0%$42.00+259.6%-20.7%$153.07MN/A-8.593High Trading VolumeCLYMClimb Bio3.0981 of 5 stars$2.04-9.3%$9.00+341.2%N/A$152.47MN/A-2.919News CoveragePositive NewsAnalyst UpgradePLXProtalix BioTherapeutics1.8954 of 5 stars$1.91+5.5%$15.00+685.3%+85.5%$152.29M$61.95M-14.69200THTXTheratechnologiesN/A$3.29-0.3%N/A+166.9%$151.73M$84.38M-17.32140 Related Companies and Tools Related Companies VTYX Alternatives TIL Alternatives CLLS Alternatives CGTX Alternatives ACOG Alternatives NVCT Alternatives GLSI Alternatives CLYM Alternatives PLX Alternatives THTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LTRN) was last updated on 9/23/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantern Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lantern Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LTRN Stock Alerts